Member Info for Bridgedogg1

A savvy investor (not me) would be buying today, at the end of the 40 day period when news and opinions can be released by management. Combine that with a depressed share price and a new CEO and its a perfect storm for a strong recovery. The current price is at around my average so Im very optimistic for the future.

The 40 day blackout are US rules because the offer of stock was marketed in the US

https://www.investopedia.com/terms/q/quietperiod.asp

"The quiet period prohibits management teams or their marketing agents from making forecasts or expressing any opinions about the value of their company."

I can’t see a Q1 production update coming purely because it would have increased.

Best analysis of the day so far is on twitter

https://x.com/mylesmcnulty/status/1785202447868121322?s=46&t=tlq1Bm3_53631l-uJoA5lQ

Looks like the shortest were spot on. They will have to close out at some point after the D4E, then it’s game on.

Some entertainment

With the the science looming after itself the shift will be to address the financial and conercial failings of the last few years. Sell off diagnostics, slice off some deals for specific indications with BP, hold on for the big prize with AVA6000. Should see some £billion takeover interest in H2 once fda approval for P2 results for orphan indications start coming in.

There are also significant partnering opportunities for the broader platform.

The value in CPX is its bank of intellectual property, very valuable to an EV manufacturer. It’s good to see the underlying business improving and developing contracts but that’s not why I bought in here. With litigation cleared and finances sorted this a sitting duck for takeover at multiples of the current share price.

I think the next big news will be another deal. Maybe multiple deals in a fairly short space of time. The drill time line is definitely being accelerated with all the activity around our licenses.

Looks like the sellers have cleared. Back up into the 50s.

The night is always darkest before the dawn

Share price at all time lows with a new ceo and multiple commercial routes to be realised shortly.

About time. Share price still very very low.

What we have:

-New CEO

-Therapeutics with holy grail of cancer drugs

-Diagnostics soon profit making to be sold

- licensing agreement with POINT Biopharma Inc

-partnerships for the Affimer platform with Daewoong Pharmaceutical and LG Chem Life Sciences.

-AffyXell developing new intellectual property

-Paying down bond

-material milestones with licensing agreements

I expect we will hear from the new CEO shortly.

Regarding cash runway, the loss reduced from £36m to £24m has around £10m of items that will not be repeated this year so the runway is atleast 12 months with £16m in the bank. I think we will have a few conercial deal before year end. Chris has worked in BP and has been driving the platform. Likely already talking to the people we will do the deals with.

Lots of differing opinions depending on your shareholder (or not status) but the market will focus on the big news which is the CEO change which signals the commercial shift in therapeutics, and the for sale sign over diagnostics.

A cash flow positive, Europe wide diagnostics division will be very attractive in the current climate. If we can sell it, pay off the bond with £30m left over that will be a great conercial move while we simultaneously licence out orphan indications to BP.

The large shareholders would have been pushing for this change and should be happier now, I think we will now get more info on the historic fundraise shortly.

Glad I picked up some more in the 48s 5 mins before close.

Lovely churn. Same again tomorrow please.

0.2p by Friday.

It seems sensible to me to assume the results have been held back to coincide with the expiry of the 40 day blackout period. Despite the positive science the financials/fund raise have been driving this down from over £1 in the last year. Some clarity on this will surely have a very positive impact on the share price. And as I've said before, mention of a US listing would be nice.

So 10x revenue is 65p per share then? Just for Diagnostics.

Worth less than what?

And the buyer is back.

If we can push through 12p then it could hit 16p fairly quickly, even before any farm out news lands